The Journal of dermatological treatment最新文献_第2页

Effect of amniotic fluid on hair follicle growth. 羊水对毛囊生长的影响。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-01-19 DOI: 10.1080/09546634.2025.2451389

Gamze Tumentemur, Elif Ganime Aygun, Bulut Yurtsever, Didem Cakirsoy, Ercument Ovali

{"title":"Effect of amniotic fluid on hair follicle growth.","authors":"Gamze Tumentemur, Elif Ganime Aygun, Bulut Yurtsever, Didem Cakirsoy, Ercument Ovali","doi":"10.1080/09546634.2025.2451389","DOIUrl":"10.1080/09546634.2025.2451389","url":null,"abstract":"Purpose: Human amniotic fluid stem cells (hAFSCs) have shown significant regenerative potential in treating hair loss, wound healing, and tissue repair. This study aims to evaluate the effects of human amniotic fluid (hAF) on hair follicle (HF) regeneration and immune system modulation.Materials and Methods: The hAF used was pooled, acellular, and gamma-irradiated to standardize its contents and enhance its stability. Both irradiated (FAFI) and non-irradiated (FAF) hAF were assessed for their efficacy and safety in promoting hair growth and modulating immune responses in a rat model of hair loss. The study examined HF regeneration, transition to the anagen phase, and macrophage polarization from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype.Results: Both FAF and FAFI treatments significantly increased HF density, with FAFI exhibiting enhanced effects. Histological analysis demonstrated improved HF regeneration, increased M2 macrophages, and reduced collagen fiber deposition in treated areas. Gamma irradiation likely improved the efficacy of FAFI by stabilizing active components and inhibiting protease activity.Conclusions: Irradiated hAF is a safe and effective therapeutic candidate for alopecia and HF growth disorders. These findings support further evaluation of hAF in clinical trials to validate its potential for hair regeneration therapies.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2451389"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Portuguese consensus on first line treatment of moderate-to-severe psoriasis with a non-TNF inhibitor therapy - a delphi methodology. 葡萄牙共识的一线治疗中重度牛皮癣与非肿瘤坏死因子抑制剂治疗-德尔菲方法。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-01-27 DOI: 10.1080/09546634.2025.2453601

Tiago Torres, Sofia Magina, Maria João Paiva Lopes

{"title":"Portuguese consensus on first line treatment of moderate-to-severe psoriasis with a non-TNF inhibitor therapy - a delphi methodology.","authors":"Tiago Torres, Sofia Magina, Maria João Paiva Lopes","doi":"10.1080/09546634.2025.2453601","DOIUrl":"10.1080/09546634.2025.2453601","url":null,"abstract":"Introduction: Psoriasis (PsO) is a common chronic, inflammatory, immune-mediated disease. In 2023, a 4.4% prevalence of PsO was reported in Portugal. Currently, Tumor Necrosis Factor inhibitors (TNFi) are the recommended first-line (1 L) biologic agents in Portugal given their lower cost. However, TNFi may not be suitable for several patients. In these patients, interleukin inhibitors (ILi) should be considered as they provide more effective outcomes and a better safety profile.Methods: Qualitative interviews with PsO experts were conducted to identify PsO biologic treatment needs, resulting in an online survey to explore clinical cases focused on subpopulations of PsO. A delphi study evaluated consensus on clinical criteria to initiate non-TNFi therapy in seven predefined subpopulations of patients.Results: This study highlights the benefit of starting non-TNFi therapy in all PsO predefined subpopulations. Patients with infection risk, mild heart failure and associated comorbidities, autoimmune diseases and family history of demyelinating disease consensually benefit from starting non-TNFi therapy in 1 L. Several risks associated with latent tuberculosis, advanced age and oncological disease were also evaluated.Conclusion: Given the existence of various risks associated with TNFi usage, this clinical perspective overview of Portuguese experts in PsO treatment emphasizes the need for a tailored therapeutic framework in the management of PsO.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2453601"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143054222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Use magnified images to help define the boundaries of melanonychia in surgery. 在手术中使用放大图像来帮助确定黑甲的边界。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-02-02 DOI: 10.1080/09546634.2025.2459153

Simin He, Siliang Xue

引用次数: 0

Abrocitinib alleviates the symptoms of Netherton syndrome and is well tolerated. 阿布替尼可减轻内瑟顿综合征的症状，耐受性良好。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-03-30 DOI: 10.1080/09546634.2024.2447883

Jun-Ting Tang, Yu-Liang Qin, Wei-Jia Zhao, Ying Tu, Dong-Jie Sun

{"title":"Abrocitinib alleviates the symptoms of Netherton syndrome and is well tolerated.","authors":"Jun-Ting Tang, Yu-Liang Qin, Wei-Jia Zhao, Ying Tu, Dong-Jie Sun","doi":"10.1080/09546634.2024.2447883","DOIUrl":"10.1080/09546634.2024.2447883","url":null,"abstract":"Purpose: To investigate the potential genetic basis of Netherton syndrome (NS) through first- and second-generation DNA sequencing techniques. Additionally, we evaluated the therapeutic efficacy of Abrocitinib in NS patients.Materials and methods: We conducted whole-exome sequencing analysis on a pedigree comprising one affected individual with NS. Subsequently, the identified patient was treated with Abrocitinib, and clinical improvements in cutaneous manifestations were systematically assessed.Results: Genetic analysis revealed that the patient harbored compound heterozygous mutations in the SPINK5 gene, including a missense mutation in exon 26 (c.2475G > T, p.Trp825Cys). Following six months of Abrocitinib therapy, the patient exhibited marked improvement in skin rash and overall disease severity.Conclusions: Our findings suggest that SPINK5 missense mutations may contribute to the pathogenesis of NS. Furthermore, Abrocitinib demonstrates promising therapeutic potential in the management of NS, warranting further investigation in larger clinical cohorts.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2447883"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143756896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Frequency and clinical features of disease flares in patients with atopic dermatitis treated with dupilumab. 杜匹单抗治疗特应性皮炎患者疾病发作的频率和临床特征

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-04-29 DOI: 10.1080/09546634.2025.2495831

Ilaria Trave, Ilaria Salvi, Giorgio Battaglia, Alice Vischi, Aurora Parodi, Emanuele Cozzani

{"title":"Frequency and clinical features of disease flares in patients with atopic dermatitis treated with dupilumab.","authors":"Ilaria Trave, Ilaria Salvi, Giorgio Battaglia, Alice Vischi, Aurora Parodi, Emanuele Cozzani","doi":"10.1080/09546634.2025.2495831","DOIUrl":"10.1080/09546634.2025.2495831","url":null,"abstract":"Background: Dupilumab, an interleukin 4 (IL-4) receptor α-antagonist approved for the treatment of atopic dermatitis, is considered effective in preventing disease recurrences. However, the incidence and characteristics od atopic dermatitis flares during treatment with dupilumab in a real-life setting have not been described in the literature.Objective: This study aims to evaluate the prevalence of disease flares in patients in treatment with dupilumab and to describe the features of flares in our study population.Methods: We conducted a retrospective observational study in which we collected demographic and clinical data on adult patients with a diagnosis of severe atopic dermatitis in treatment with dupilumab for a minimum of six months, who reached EASI75 within six months of treatment initiation.Results: Ninety-nine patients were enrolled. Recurrences were recorded for 38.4% of patients and 7.1% developed a second recurrence. The EASI at recurrence was always lower than the EASI before treatment initiation. The localization of disease at head and neck before treatment was associated to the same localization of disease at the first recurrence (p = 0.011). The risk of recurrence was associated to the baseline EASI score (p = 0.005). The presence of dupilumab-related conjunctivitis was significantly associated to recurrences (p = 0.02).Conclusions: Treatment with dupilumab does not exclude the risk of a relapse, which can be estimated around 50% within a timespan of three years. In the most cases, flares should not be regarded as treatment failures, and can be easily managed with additional treatment.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2495831"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144033242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patient awareness and perspectives on psoriatic disease: results of the psoriasis and beyond survey from the Gulf region. 患者对银屑病的认识和看法：海湾地区银屑病和其他疾病调查的结果。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-06-04 DOI: 10.1080/09546634.2025.2485254

Fatima Albreiki, Amani Alfalasi, Mohammed Al-Otaibi, Ahmed Ameen, Abeer Bazali, Martin Steinhoff, Saud Al Hashmi, Atlal Al-Lafi

{"title":"Patient awareness and perspectives on psoriatic disease: results of the psoriasis and beyond survey from the Gulf region.","authors":"Fatima Albreiki, Amani Alfalasi, Mohammed Al-Otaibi, Ahmed Ameen, Abeer Bazali, Martin Steinhoff, Saud Al Hashmi, Atlal Al-Lafi","doi":"10.1080/09546634.2025.2485254","DOIUrl":"https://doi.org/10.1080/09546634.2025.2485254","url":null,"abstract":"Background: Psoriatic disease (PsD) is a chronic immune-mediated condition with substantial humanistic burden. Despite guidelines emphasizing patient awareness for effective management, many individuals remain uninformed about its systemic nature and associated comorbidities.Aim: This study assessed PsD patient awareness in the Gulf region using the 'Psoriasis and Beyond' survey.Materials and methods: A cross-sectional online survey was conducted from March 2022 to June 2023, involving adult patients with moderate-to-severe psoriasis from the United Arab Emirates (UAE), Kuwait, Qatar, and Oman. Clinical characteristics and patient awareness data were collected.Results: Among 346 patients (52 with psoriatic arthritis, PsA), 63% were aware of the term 'PsD,' with higher awareness among those with both psoriasis and PsA. However, only 61% recognized its systemic nature. Quality of life (QoL) was significantly affected in 28% of respondents, particularly those with both psoriasis and PsA. Stigma and discrimination were reported by 73% of patients. While 37% had some knowledge about PsD, many perceived their health as beyond their control.Conclusion: The study identifies a significant knowledge gap among PsD patients in the Gulf region, highlighting the need for enhanced patient education and improved communication with healthcare providers.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2485254"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144218008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Potential clinical factors associated with secukinumab dose selection in the treatment of hidradenitis suppurativa: a cohort study of 132 patients. 与secukinumab剂量选择治疗化脓性汗腺炎相关的潜在临床因素：132例患者的队列研究

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-06-04 DOI: 10.1080/09546634.2025.2512156

Alberto Soto Moreno, Sofía Haselgruber, Giovanna F Osorio-Gomez, Pablo Fernandez-Crehuet, Juan Ortiz-Alvarez, Juan M Segura-Palacios, Pedro Navarro-Guillamon, Alicia Padial Gomez-Torrente, Maria D Fernandez-Ballesteros, Jose M Llamas-Molina, Fiorella Vasquez-Chinchay, Claudia Guerrero-Ramirez, Marisol Contreras-Steyls, Marina Romero-Bravo, Alejandro Molina-Leyva

引用次数: 0

A network meta-analysis study of monotherapies for hidradenitis suppurativa: analyses of the current evidence base. 化脓性汗腺炎单一疗法的网络荟萃分析研究：当前证据基础分析。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-06-04 DOI: 10.1080/09546634.2025.2513054

Aditya K Gupta, Mary A Bamimore, Vasiliki Economopoulos, Mesbah Talukder, Vincent Piguet, Renata Magalhaes

{"title":"A network meta-analysis study of monotherapies for hidradenitis suppurativa: analyses of the current evidence base.","authors":"Aditya K Gupta, Mary A Bamimore, Vasiliki Economopoulos, Mesbah Talukder, Vincent Piguet, Renata Magalhaes","doi":"10.1080/09546634.2025.2513054","DOIUrl":"10.1080/09546634.2025.2513054","url":null,"abstract":"Background: The number of monotherapies for hidradenitis suppurativa (HS) has expanded. However, the efficacy of active comparators has not been determined in head-to-head trials.Aims: We conducted an NMA to determine the relative efficacy and safety of monotherapies for HS.Methods: The literature was systematically reviewed to obtain data from trials that (1) were published in English, (2) investigated a systemically administered monotherapy with an immunomodulatory agent (3) randomized, and (4) quantified efficacy, at 16 weeks, insofar as the Hidradenitis Suppurativa Clinical Response 50 (HiSCR-50), Dermatology Life Quality Index (DLQI) and Numeric Rating Scale 30 (NRS30). For safety, we analyzed the occurrence of treatment-emergent adverse events (TEAEs). For sensitivity analyses, we conducted network meta-regressions adjusted for age and sex.Results: We determined the efficacy of numerous regimens including those approved by the United States FDA; for instance, the FDA-approved 'bimekizumab 320 mg every 2 weeks' was more efficacious than 'IFX-1 800 mg every 2 weeks' (odd ratio = 1.99, 95% credible interval: 1.09,3.87, p < 0.05) in terms of HiSCR-50. Sensitivity analyses showed that the main analyses were robust. Overall, risk of bias across studies was low.Conclusions: The current NMA provides comparative evidence on systematic immunomodulatory HS monotherapies from the most up-to-date trial evidence.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2513054"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144218004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ruxolitinib cream monotherapy for facial and/or neck atopic dermatitis: results from a decentralized, randomized phase 2 clinical trial. 鲁索利替尼乳膏单药治疗面部和/或颈部特应性皮炎：一项分散、随机的2期临床试验的结果

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-03-25 DOI: 10.1080/09546634.2025.2480744

Zelma C Chiesa Fuxench, Zhihong Lai, YuTzu Kuo, Haq Nawaz, Jonathan Cotliar

{"title":"Ruxolitinib cream monotherapy for facial and/or neck atopic dermatitis: results from a decentralized, randomized phase 2 clinical trial.","authors":"Zelma C Chiesa Fuxench, Zhihong Lai, YuTzu Kuo, Haq Nawaz, Jonathan Cotliar","doi":"10.1080/09546634.2025.2480744","DOIUrl":"10.1080/09546634.2025.2480744","url":null,"abstract":"Purpose: Ruxolitinib cream was evaluated in patients with facial/neck atopic dermatitis (AD) in a decentralized, double-blind, randomized clinical trial (NCT05127421).Materials and methods: Patients aged 12-70 years with AD (Investigator's Global Assessment [IGA] score 2/3, ≤20% affected body surface area [face/neck, ≥0.5%]) were randomized 2:1 to twice-daily 1.5% ruxolitinib cream or vehicle for 4 weeks; thereafter, all patients applied as-needed ruxolitinib cream for 4 additional weeks. The primary endpoint was ≥75% improvement in head/neck Eczema Area and Severity Index (EASI-75) at Week 4 assessed by blinded central reader using photographs.Results: Among 77 randomized patients (median [range] age, 38.0 [17-66] y), 44.2% were Black. The mean (SD) baseline head/neck EASI was 1.2 (0.7). More patients who applied ruxolitinib cream vs vehicle achieved head/neck EASI-75 at Week 4 (37.0% vs 17.4%; p = 0.091). Improvements with ruxolitinib cream vs vehicle were observed for facial/neck IGA treatment success (IGA 0/1 with ≥2-point improvement from baseline) and Patient-Oriented Eczema Measure (overall and itch). Ruxolitinib cream was well tolerated, including on the face and neck. Application site reactions were infrequent (ruxolitinib cream, 1.9% [n = 1]; vehicle, 8.7% [n = 2]).Conclusions: Ruxolitinib cream improved signs and symptoms of facial/neck AD vs vehicle and was well tolerated.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2480744"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143712640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lebrikizumab improves head/neck/face dermatitis and erythema and does not increase treatment-emergent adverse events of head/neck/face erythema in patients with moderate-to-severe atopic dermatitis. Lebrikizumab改善头颈部/面部皮炎和红斑，并且不会增加中度至重度特应性皮炎患者头颈部/面部红斑治疗后出现的不良事件。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-07-24 DOI: 10.1080/09546634.2025.2492188

Jenny E Murase, Kilian Eyerich, Raj Chovatiya, H Chih-Ho Hong, Christine Bangert, Lindsay Strowd, Mette Deleuran, Amber Reck Atwater, Maria Jose Rueda, Hany Elmaraghy, Maria Lucia Buziqui Piruzeli, Ignasi Pau-Charles, Fan Emily Yang, Jinglin Zhong, Delphine Staumont-Sallé

{"title":"Lebrikizumab improves head/neck/face dermatitis and erythema and does not increase treatment-emergent adverse events of head/neck/face erythema in patients with moderate-to-severe atopic dermatitis.","authors":"Jenny E Murase, Kilian Eyerich, Raj Chovatiya, H Chih-Ho Hong, Christine Bangert, Lindsay Strowd, Mette Deleuran, Amber Reck Atwater, Maria Jose Rueda, Hany Elmaraghy, Maria Lucia Buziqui Piruzeli, Ignasi Pau-Charles, Fan Emily Yang, Jinglin Zhong, Delphine Staumont-Sallé","doi":"10.1080/09546634.2025.2492188","DOIUrl":"https://doi.org/10.1080/09546634.2025.2492188","url":null,"abstract":"Purpose of the study: Head, neck (HN), and face involvement in atopic dermatitis (AD) poses a major psychological burden and can be challenging to effectively treat. New appearance of HN dermatitis has been reported with biologics used to treat AD. Lebrikizumab (LEBRI), a monoclonal targeting IL-13, is approved for AD treatment in the US, Europe and Asia. We evaluated HN dermatitis improvement using the HN Eczema Area and Severity Index (EASI) and a facial dermatitis questionnaire, along with safety evaluations focusing on HN and facial erythema.Materials and methods: Efficacy analyses were performed on placebo (PBO) controlled modified intention-to-treat (mITT) populations from the 16-week induction periods of ADvocate1 and ADvocate2 (pooled) and ADhere studies. Treatment-emergent adverse events (TEAEs) of HN and facial erythema were summarized from eight Phase 2 and 3 clinical trials.Results: LEBRI resulted in significantly greater improvements than PBO in EASI HN subscore as early as Week 2 (ADvocate 1&2), with 68.1% improvement at Week 16.Conclusions: LEBRI improved EASI HN subscore and HN EASI clinical signs of erythema and facial dermatitis at Week 16. During the PBO-controlled period, an increased reporting of HN and facial erythema as TEAE was not observed in the LEBRI group and HN and facial TEAEs reporting did not increase with longer exposure.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2492188"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144710431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0